Unknown

Dataset Information

0

Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.


ABSTRACT: Progressive multifocal leukoencephalopathy (PML), a rare devastating demyelinating disease caused by the polyomavirus JC (JCV), occurs in severely immunocompromised patients, most of whom have advanced-stage HIV infection. Despite combination antiretroviral therapy (cART), 50% of patients die within 6 months of PML onset. We conducted a multicenter, open-label pilot trial evaluating the survival benefit of a five-drug cART designed to accelerate HIV replication decay and JCV-specific immune recovery.All the patients received an optimized cART with three or more drugs for 12 months, plus the fusion inhibitor enfuvirtide during the first 6 months. The main endpoint was the one-year survival rate. A total of 28 patients were enrolled. At entry, median CD4+ T-cell count was 53 per microliter and 86% of patients had detectable plasma HIV RNA and CSF JCV DNA levels. Seven patients died, all before month 4. The one-year survival estimate was 0.75 (95% confidence interval, 0.61 to 0.93). At month 6, JCV DNA was undetectable in the CSF of 81% of survivors. At month 12, 81% of patients had undetectable plasma HIV RNA, and the median CD4+ T-cell increment was 105 per microliter. In univariate analysis, higher total and naive CD4+ T-cell counts and lower CSF JCV DNA level at baseline were associated with better survival. JCV-specific functional memory CD4+ T-cell responses, based on a proliferation assay, were detected in 4% of patients at baseline and 43% at M12 (P?=?0.008).The early use of five-drug cART after PML diagnosis appears to improve survival. This is associated with recovery of anti-JCV T-cell responses and JCV clearance from CSF. A low CD4+ T-cell count (particularly naive subset) and high JCV DNA copies in CSF at PML diagnosis appear to be risk factors for death.ClinicalTrials.gov NCT00120367.

SUBMITTER: Gasnault J 

PROVIDER: S-EPMC3127950 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature

altmetric image

Publications

Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.

Gasnault Jacques J   Costagliola Dominique D   Hendel-Chavez Houria H   Dulioust Anne A   Pakianather Sophie S   Mazet Anne-Aurélie AA   de Goer de Herve Marie-Ghislaine MG   Lancar Rémi R   Lascaux Anne-Sophie AS   Porte Lydie L   Delfraissy Jean-François JF   Taoufik Yassine Y  

PloS one 20110630 6


<h4>Background</h4>Progressive multifocal leukoencephalopathy (PML), a rare devastating demyelinating disease caused by the polyomavirus JC (JCV), occurs in severely immunocompromised patients, most of whom have advanced-stage HIV infection. Despite combination antiretroviral therapy (cART), 50% of patients die within 6 months of PML onset. We conducted a multicenter, open-label pilot trial evaluating the survival benefit of a five-drug cART designed to accelerate HIV replication decay and JCV-s  ...[more]

Similar Datasets

| S-EPMC2919371 | biostudies-other
| S-EPMC3072716 | biostudies-literature
| S-EPMC8714204 | biostudies-literature
| S-EPMC4628054 | biostudies-literature
| S-EPMC4863751 | biostudies-other
| S-EPMC8739669 | biostudies-literature
| S-EPMC3256289 | biostudies-literature
| S-EPMC9291129 | biostudies-literature
| S-EPMC5544784 | biostudies-literature
| S-EPMC9759507 | biostudies-literature